Skip to content
Wednesday 12 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,833.15
-0.10%
DAX
26,331.07
-0.23%
CAC 40
8,674.94
-0.46%
STOXX 50
6,533.99
-0.26%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 16 July 2014 4:34 am  |  Updated:  Friday 07 June 2019 1:13 am

Google and Novartis join forces to develop contact lens for diabetics

By: Joe Storey

Add as a preferred source on Google

Swiss drugmaker Novartis yesterday struck an agreement with Google to develop “smart” contact lenses that would help diabetics to track their blood glucose levels or restore the eye’s ability to focus.

The device would measure glucose in tear fluid and send the data wirelessly to a mobile device, Novartis said. The technology is potentially life-changing for many diabetics, who prick their fingers as many as 10 times daily to check their body’s production of the sugar.

Diabetes affects 382m people around the world and the technology would allow Novartis to compete in a global blood-sugar tracking market that is expected to be worth more than $12bn by 2017.

Novartis chief executive Joseph Jimenez said: “[This] is the Holy Grail of vision care, to be able to replicate the natural functioning of the eye,” adding that Novartis aimed to have the product on the market within five years.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Google

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • It’s not just Jason Arday, most of sociology is a scam

  • Hargreaves Lansdown orders staff back to office

More from Morning Wire

  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

    Business Wire
  • This Is the Moment Everything Changed: Ascensia Launches Global Art and Photography Competition for World Diabetes Day

    Business Wire
  • Azalea Vision Appoints Co-Founder Andrés Vasquez Quintero as Chief Executive Officer to Lead Next Phase of Clinical Development

    Business Wire
  • ITC Infotech and Google Cloud Join Hands to Scale Enterprise Agentic Transformation and AI Innovation

    Business Wire
  • ustwo brings AI governance to the boardroom with appointment of Google DeepMind executive Simon Bouton

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook